PNC Financial Services Group
KYTX icon

PNC Financial Services Group’s Kyverna Therapeutics KYTX Stock Holding History

PNC Financial Services Group’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.2K Sell
1,530
-138
-8% -$1.15K ﹤0.01% 3855
2025
Q4 		$15.7K Hold
1,668
– – ﹤0.01% 3774
2025
Q3 		$10K Sell
1,668
-282
-14% -$1.13K ﹤0.01% 3940
2025
Q2 		$5.99K Buy
1,950
+480
+33% +$1.19K ﹤0.01% 4056
2025
Q1 		$2.84K Buy
+1,470
New +$4.34K ﹤0.01% 4250

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

PNC Financial Services Group's KYTX Position: Q1 2026 in Review

PNC Financial Services Group reduced its Kyverna Therapeutics (KYTX) stake by 8.3% in Q1 2026, selling an estimated $1.15K and leaving 1,530 shares worth $13.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3855.

PNC Financial Services Group first reported a position in KYTX in Q1 2025 and has held it in 5 quarters since. The position peaked at $15.7K in Q4 2025. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • PNC Financial Services Group held 1,530 shares of Kyverna Therapeutics worth $13.2K as of Q1 2026.
  • PNC Financial Services Group sold 138 Kyverna Therapeutics shares in Q1 2026, an estimated $1.15K.
  • Kyverna Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q1 2026, its #3855 holding.
  • PNC Financial Services Group first reported a position in Kyverna Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • PNC Financial Services Group's Kyverna Therapeutics position peaked at $15.7K in Q4 2025.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on PNC Financial Services Group's 13F filing for Q1 2026, filed 8 May 2026.